Adaptin Bio APTN
OTC APTN
$6.27 +0.00 (+0.00%)
At close: Aug 19, 2026 · 4:00 PM EDT

Adaptin Bio (APTN) Amortization of Deferred Charges (2024 - 2025)

Updated

Analysis

Adaptin Bio (APTN) Amortization of Deferred Charges (2024 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,144.36 Bn 1,112.95 Bn 19.71 Bn
2 Johnson & Johnson 635.36 Bn 555.22 Bn 17.30 Bn
3 AbbVie 502.79 Bn 475.90 Bn 12.70 Bn
4 Merck 356.08 Bn 310.46 Bn 12.21 Bn
5 Novartis Ag 300.87 Bn 264.86 Bn 11.24 Bn
6 Astrazeneca 264.31 Bn 237.99 Bn 12.86 Bn
7 Amgen 239.07 Bn 194.47 Bn 7.24 Bn
8 Gilead Sciences 194.50 Bn 168.70 Bn 6.22 Bn
9 Pfizer 171.00 Bn 117.64 Bn 10.94 Bn
10 Adaptin Bio 56.76 Mn 54.75 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 53,722.00
Dec 31, 2024 108,389.00
Sep 30, 2024 81,853.00
Jun 30, 2024 22,881.00
Mar 31, 2024 26,666.00
API Access

Adaptin Bio Amortization of Deferred Charges API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=amortization-of-deferred-charges&ticker=APTN&period=max&api_key=YOUR_API_KEY